The JAK inhibitor cerdulatinib was active against MYB-TYK2 fusion B-cell ALL in vitro and in vivo and has the potential to become a possible treatment option for high-risk ALL patients with MYB-TYK2 fusion[175]. Here, MYB is linked to acute lymphoblastic leukemia.